APOLLON GENEVAX VACCINE TO ENTER CLINIC IN MAY FOR HIV AND T CELL LYMPHOMA; "GENERIC" MANUFACTURING PROVIDES INEXPENSIVE SUPPLY OF GENE THERAPY PRODUCT
Executive Summary
Clinical trials of facilitated DNA Genevax products for HIV infection and T cell lymphoma could begin by the end of May, according to the corporate sponsor, Apollon, Inc. The Malvern, Penn.-based firm filed INDs in late 1994 for Genevax products for the two indications. Genevax vaccine products use specific sequences of DNA to elicit responses from the immune system when injected intramuscularly.